| Literature DB >> 22079057 |
Ragy R Girgis1, Mark Slifstein2, Xiaoyan Xu2, W Gordon Frankle3, Evdokia Anagnostou4, Stacey Wasserman5, Lauren Pepa5, Alexander Kolevzon5, Anissa Abi-Dargham2, Marc Laruelle6, Eric Hollander7.
Abstract
Evidence from biochemical, imaging, and treatment studies suggest abnormalities of the serotonin system in autism spectrum disorders, in particular in frontolimbic areas of the brain. We used the radiotracers [(11)C]MDL 100907 and [(11)C]DASB to characterize the 5-HT(2A) receptor and serotonin transporter in Asperger's Disorder. Seventeen individuals with Asperger's Disorder (age=34.3 ± 11.1 years) and 17 healthy controls (age=33.0 ± 9.6 years) were scanned with [(11)C]MDL 100907. Of the 17 patients, eight (age=29.7 ± 7.0 years) were also scanned with [¹¹C]DASB, as were eight healthy controls (age=28.7 ± 7.0 years). Patients with Asperger's Disorder and healthy control subjects were matched for age, gender, and ethnicity, and all had normal intelligence. Metabolite-corrected arterial plasma inputs were collected and data analyzed by two-tissue compartment modeling. The primary outcome measure was regional binding potential BP(ND). Neither regional [¹¹C]MDL 100907 BP(ND) nor [¹¹C]DASB BP(ND) was statistically different between the Asperger's and healthy subjects. This study failed to find significant alterations in binding parameters of 5-HT(2A) receptors and serotonin transporters in adult subjects with Asperger's disorder.Entities:
Mesh：
Substances：
Year: 2011 PMID： 22079057 PMCID： PMC3225493 DOI： 10.1016/j.pscychresns.2011.04.007
Source DB: PubMed Journal: Psychiatry Res ISSN： 0165-1781 Impact factor: 3.222